SCHEMBL30434733

SCHEMBL30434733

O=c1[nH]nc2c(Br)c(-c3ccccc3)ncn12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 5/20 0.55
PDE3B Q13370 7/20 0.54
PDE3A Q14432 7/20 0.54
PDE1A P54750 6/20 0.51
PDE1B Q01064 6/20 0.51
PDE1C Q14123 6/20 0.51
LTK P29376 2/20 0.49
ALK Q9UM73 2/20 0.49
DYRK1B Q9Y463 2/20 0.49
DYRK1A Q13627 2/20 0.49
CLK4 Q9HAZ1 2/20 0.49
RET P07949 1/20 0.49
MET P08581 1/20 0.49
GRK5 P34947 1/20 0.49
CDK8 P49336 1/20 0.49
RPS6KA3 P51812 1/20 0.49
MST1R Q04912 1/20 0.49
TYRO3 Q06418 1/20 0.49
LRRK2 Q5S007 1/20 0.49
XDH P47989 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4841633 0.77 PDE3B (0.48) PDE5APDE3BPDE3APDE1APDE1B
SCHEMBL30268976 0.75 ADORA2A (0.48) PDE5APDE3BPDE3APDE1APDE1B
SCHEMBL30361793 0.73 PDE3B (0.44) PDE5APDE3BPDE3APDE1APDE1B
SCHEMBL23858671 0.72 PDE3B (0.57) PDE5APDE3BPDE3APDE1APDE1B
SCHEMBL7422898 0.69 KDM4E (0.55) PDE5APDE3BPDE3ALTKALK
SCHEMBL23858893 0.69 PDE3B (0.48) PDE5APDE3BPDE3APDE1APDE1B
SCHEMBL30361845 0.69 ADORA2A (0.44) PDE5APDE3BPDE3APDE1APDE1B
SCHEMBL30218238 0.69 ADORA2A (0.44) PDE5APDE3BPDE3APDE1APDE1B
SCHEMBL3522789 0.68 PDE5A (0.58) PDE5APDE3BPDE3APDE1APDE1B
SCHEMBL10845661 0.67 NSD3 (0.49) CLK4XDHKDRHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528815-B2 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer NXERA PHARMA UK LIMITED (GB) 2026-01-20 US disclosed
CN-115867280-B 5-Amino-8- (4-pyridyl) - [1,2,4] triazolo [4,3-C ] pyrimidin-3-one compounds for anticancer use 奈克斯拉制药英国有限公司 2025-05-27 CN disclosed
US-20230146483-A1 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER NXERA PHARMA UK LIMITED (GB) 2023-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230146483-A1 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER ADORA2A, ADORA1, ADORA3 PDE5A 163/4885PDE3B 251/4885PDE3A 180/4885
US-12528815-B2 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer ADORA1, ADORA3, OPRL1 PDE5A 1599/4885PDE3B 1664/4885PDE3A 1508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.